MacroGenics, Inc. (MGNX) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. MacroGenics, Inc. is a biopharmaceutical company developing antibody-based therapeutics for cancer, utilizing proprietary platforms for antibody-drug conjugates (ADCs) and multi-specific antibodies. The company operates a commercial-scale manufacturing facility and relies heavily on strategic collaborations for funding and development. As of November 7, 2025, there were 63,258,532 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $72.8 million | $110.7 million | $108.3 million | $130.6 million |
| Net Income (Loss) | $16.8 million | $56.3 million | $(60.5) million | $(51.5) million |
| EPS (Diluted) | $0.27 | $0.90 | $(0.96) | $(0.82) |
| Operating Cash Flow | N/A | N/A | $(124.1) million | $(30.0) million |
| Cash & Equivalents | $80.1 million | $182.8 million (Dec 2024) | $80.1 million | $179.6 million (Sep 2024) |
| Marketable Securities | $66.3 million | $18.8 million (Dec 2024) | $66.3 million | $18.8 million (Dec 2024) |
| Total Debt / Royalty Liability | $70.3 million | $0 | $70.3 million | $0 |
Note: The "Liability related to future royalties" of $70.3 million represents a financing arrangement from the sale of royalty rights, not traditional debt.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 34% in Q3 2025 compared to Q3 2024. This was primarily driven by a $100 million milestone recognized in Q3 2024 from Incyte (retifanlimab) versus a $50 million milestone recognized in Q3 2025 from Sanofi (TZIELD). Additionally, product sales from MARGENZA ceased after the asset was sold to TerSera Therapeutics in late 2024.
- Contract Manufacturing Growth: Contract manufacturing revenue surged 340% in Q3 2025 ($19.8 million vs. $4.6 million) due to increased production volumes for partners.
- Profitability Shift: The company reported a net income of $16.8 million in Q3 2025, a significant improvement from the $56.3 million net income in Q3 2024, though the YTD 2025 period remains in a net loss of $60.5 million.
- Expense Reduction: R&D expenses decreased 19% in Q3 2025 ($32.7 million vs. $40.5 million) due to the discontinuation of the vobra duo program and reduced costs for MGC028 and margetuximab. SG&A expenses dropped 30% ($9.9 million vs. $14.1 million) due to lower stock-based compensation and professional fees.
- Liquidity Event: In June 2025, the company sold royalty rights for ZYNYZ to Sagard Healthcare Partners for $70 million, recorded as a liability. This provided significant cash inflow ($69.7 million net) in financing activities.
Guidance, Outlook, and Risks
- Cash Runway: Management anticipates that current cash, marketable securities, the $50 million receivable from Sanofi, and future partner payments will support operations into late 2027.
- Cost Initiatives: The company is executing cost-saving measures to extend its financial runway while advancing its pipeline.
- Key Pipeline Assets: Focus remains on lorigerlimab (PD-1/CTLA-4), MGC026 (B7-H3 ADC), and MGC028 (ADAM9 ADC).
- Subsequent Event: Post-quarter, Gilead nominated a second research program and exercised an option, obligating them to pay $25 million to MacroGenics.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the ability to raise additional capital if needed, reliance on collaborators for commercialization, and the impact of macroeconomic conditions on funding availability.
Investor Verification Checklist
- Sanofi Receivable: Verify the collection status of the $50 million receivable from Sanofi related to regulatory milestones, which is currently booked as an asset.
- Royalty Liability Amortization: Monitor the effective interest rate (approx. 18.6%) and future cash outflows associated with the $70.3 million royalty liability to Sagard.
- Contract Manufacturing Sustainability: Assess the long-term demand for contract manufacturing services, which drove a significant portion of recent revenue growth.
- Clinical Milestones: Track progress on lorigerlimab and MGC026/MGC028, as future revenue is heavily dependent on achieving development milestones with partners like Incyte and Gilead.
- Capital Needs: Evaluate the sufficiency of the projected cash runway into late 2027 against potential delays in clinical programs or slower-than-expected partner payments.